Clinical Trials
3 trialsNCT07408635 2026-02-13
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Recruiting
NCT07135882 2025-08-22
PRIME-Lung
Trans Tasman Radiation Oncology Group
Phase 3 Not yet recruiting
NCT04124731 2019-10-11
Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)
Shanghai Chest Hospital
Phase 2 Unknown